MedTrace Logo

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

NCT02267317 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-03-04

Study results available
· View outcomes & findings →

Summary

To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.

Conditions

  • Insulin Sensitivity

Interventions

DRUG

Eritoran

Pharmacologic inhibitor of TLR4 receptors.

DRUG

D5W

5% Dextrose Water = Vehicle

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Nicolas Musi, MD · Audie L. Murphy VA Hospital, STVHCS San Antonio, Texas, United States 78229

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02267317 on ClinicalTrials.gov